Clostridium difficile: Recent epidemiologic findings and advances in therapy

Pharmacotherapy

Volumn 27, Issue 7, 2007, Pages 1029-1039

  McMaster Baxter, Nicole L ^a,b   Musher, Daniel M ^a,c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bacitracin; C. Difficile associated disease; CDAD; Clostridium difficile; Fusidic acid; Infectious diarrhea; Metronidazole; Nitazoxanide; PAR 101; Rifaximin; Teicoplanin; Tolevamer; Vancomycin

Indexed keywords

BACITRACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE VACCINE; FUSIDIC ACID; METRONIDAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CDA1; MONOCLONAL ANTIBODY MDX 1388; NITAZOXANIDE; PAR 101; PROBIOTIC AGENT; RIFAXIMIN; TEICOPLANIN; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; BACTERIAL INFECTION; CELL PROLIFERATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE; COLON MUCOSA; DIARRHEA; FEVER; HUMAN; LEUKOCYTOSIS; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS;

EID: 34250802544     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.7.1029     Document Type: Review

References (95)

1. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005;173:1037-42.
2. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004;189:1585-9.
3. Sunenshine RH, McDonald LC. Clostridium difficile- associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006;73:187-97.
4. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
5. Starr J. Clostridium difficile-associated diarrhoea: diagnosis and treatment. BMJ 2005;331:498-501.
6. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996;40:2266-70.
7. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000;38:387-94.
8. Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile [letter]. N Engl J Med 2006;354:1199-203; author reply 203.
9. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk: four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:120-5.
10. Centers for Disease Control and Prevention. Information for healthcare providers. August 2004. Available from www.cdc.gov/ncidod/dhqp/ id_cdiffFAQ_HCP.html. Accessed December 13, 2005.
11. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53.
12. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995;36:673-9.
13. Hall IC, O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe: Bacillus difficilis. Am J Dis Child 1935;48:390-402.
14. Anonymous. Antibiotics, staphylococcal enteritis and pseudomembranous enterocolitis. N Engl J Med 1953;249:37-40.
15. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974;81:429-33.
16. Bartlett JG. Commentary: Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701. J Infect Dis 2004;190:202-9.
17. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978;75:778-82.
18. Weir E, Flegel K. Protecting against Clostridium difficile illness. Can Med Assoc J 2005;172:1178.
19. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004;22:848-56.
20. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10.
21. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561-7.
22. Centers for Disease Control and Prevention. Frequently asked questions: information for healthcare providers. Clostridium difficile - general Information, 2004. Available from http://www.cdc.gov/ncidod/dhqp/ id_CdiffFAQ_general.html. Accessed December 20, 2006.
23. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
24. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
25. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5.
26. Khurana A, Vinayek N, Recco RA, Go ES, Zaman MM. The incidence of Clostridium difficile-associated and non-C. difficile-associated diarrhea after use of gatifloxacin and levofloxacin in an acute-care facility. Clin Infect Dis 2004;39:602-3.
27. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. Can Med Assoc J 2004;171:51-8.
28. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004;171:33-8.
29. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
30. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005;40:265-72.
31. McCoubrey J, Starr J, Martin H, Poxton IR. Clostridium difficile in a geriatric unit: a prospective epidemiological study employing a novel S-layer typing method. J Med Microbiol 2003;52(pt 7):573-8.
32. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93.
33. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002;40:3470-5.
34. Noren T. Outbreak from a high-toxin intruder: Clostridium difficile. Lancet 2005;366:1053-4.
35. Van Steenbergen J, Debast S, van Kregten E, van den Berg R, Notermans D, Kuijper E. Isolation of Clostridium difficile ribotype 027, toxinotype III in the Netherlands after increase in C. difficile associated diarrhoea. Eurosurveillance Weekly 2005, vol 10, issue 28. Available from http://www.eurosurveillance.org/ew/2005/050714.asp#1.
36. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001;32:331-51.
37. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
38. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med 2001;161:525-33.
39. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10.
40. Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudo-membranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001;135:434-8.
41. Barbut F, Kajzer C, Planas N, Petit JC. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 1993;31:963-7.
42. Lozniewski A, Rabaud C, Dotto E, Weber M, Mory F. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of premier cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001;39:1996-8.
43. Peterson LR, Kelly PJ, Nordbrock HA. Role of culture and toxin detection in laboratory testing for diagnosis of Clostridium difficile-associated diarrhea. Eur J Clin Microbiol Infect Dis 1996;15:330-6.
44. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003;115:543-6.
45. Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Chn Infect Dis 2002;34:1585-92.
46. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 1995;123:835-40.
47. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile- associated diarrhoea and colitis. Lancet 1983;2:1043-6.
48. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90.
49. Dzink J, Bartlett JG. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother 1980;17:695-8.
50. Biavasco F, Manso E, Varaldo PE. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 1991;35:195-7.
51. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E test. Diagn Microbiol Infect Dis 1999;34:1-6.
52. Cheng SH, Chu FY, Lo SH, Lu JJ. Antimicrobial susceptibility of Clostridium difficile by E test. J Microbiol Immunol Infect 1999;32:116-20.
53. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253-66.
54. Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 2002;20:270-4.
55. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647-50.
56. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978;2:226-8.
57. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269:71-5.
58. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-18.
59. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic-associated colitis due to Clostridium difficile. Gut 1986;27:1169-72.
60. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001;32:331-51.
61. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
62. Kasper DL, Zaleznik DF. Gas gangrene, antibiotic-associated colitis, and other clostridial infections. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill, 2001:922-7.
63. Trudel JL, Deschenes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 1995;38:1033-8.
64. Elinav E, Planer D, Gatt ME. Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis. Int J Colorectal Dis 2004;19:273-6.
65. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89:1038-45.
66. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986;146:1101-4.
67. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992;36:2192-6.
68. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004;54:211-16.
69. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005(1):CD004610.
70. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006;4:320-4.
71. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44:2254-8.
72. White AC Jr. Nitazoxanide: an important advance in antiparasitic therapy. Am J Trop Med Hyg 2003;68:382-3.
73. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7.
74. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006;42:541-7.
75. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-2.
76. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolanos M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-902.
77. Mogg GA, Arabi Y, Youngs D, et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl 1980(suppl 22):41-5.
78. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 1982;69:137-9.
79. Parmar MS. Treating C. difficile [author reply]. Can Med Assoc J 2005;172:448.
80. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001;45:2340-7.
81. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411-20.
82. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361. Available from http://www.bmj.com/cgi/content/full/324/7350/1361.
83. Cavagnaro C, Berezin S, Medow MS. Corticosteroid treatment of severe, non-responsive Clostridium difficile-induced colitis. Arch Dis Child 2003;88:342-4.
84. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-70.
85. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:640-5.
86. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991;59:2215-18.
87. Babcock GJ, Esshaki DJ, Thomas WD Jr, Ambrosino DM. Human monoclonal antibody against toxin A protects hamsters from Clostridium difficile disease. Presented at the 42nd annual meeting of the Infectious Disease Society of America, Boston, MA, September 30-October 3, 2004.
88. Lipsett PA, Samantaray DK, Tam ML, Bartlett JG, Lillemoe KD. Pseudomembranous colitis: a surgical disease? Surgery 1994;116:491-6.
89. Medich DS, Lee KK, Simmons RL, Grubbs PE, Yang HC, Showalter DP. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 1992;127:847-52; discussion 52-3.
90. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758-64.
91. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 1998;93:1873-6.
92. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004;38:414-18.
93. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force. Infect Control Hosp Epidemiol 2002;23(suppl 12):S3-40.
94. Louie TJ. How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile? Can Med Assoc J 2005;173:1049-50.
95. Centers for Disease Control and Prevention, Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):1-125, CE1-7. (Erratum in MMWR Recomm Rep 2004;53:396.)